Bright Minds Biosciences Net Income

DRUG Stock  USD 75.97  2.89  3.95%   
As of the 7th of February, Bright Minds shows the Risk Adjusted Performance of 0.1275, mean deviation of 3.52, and Downside Deviation of 4.09. Bright Minds Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Bright Minds Biosciences information ratio, as well as the relationship between the potential upside and kurtosis to decide if Bright Minds Biosciences is priced correctly, providing market reflects its regular price of 75.97 per share. Given that Bright Minds has jensen alpha of 0.5137, we suggest you to validate Bright Minds Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.
Bright Minds' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Bright Minds' valuation are provided below:
Market Capitalization
725.6 M
Earnings Share
(1.30)
There are over one hundred nineteen available fundamental signals for Bright Minds Biosciences, which can be analyzed over time and compared to other ratios. Active traders should verify all of Bright Minds Biosciences prevailing fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. The Bright Minds' current Market Cap is estimated to increase to about 548.5 M. The Bright Minds' current Enterprise Value is estimated to increase to about 470.3 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
Last ReportedProjected for Next Year
Net Loss-13.5 M-12.8 M
Net Loss-11 M-10.5 M
Net Loss-11 M-11.6 M
Net Loss(2.04)(2.15)
Net Income Per E B T 0.91  0.80 
The Bright Minds' current Net Loss is estimated to increase to about (12.8 M). The Bright Minds' current Net Loss is estimated to increase to about (10.5 M).
  
Build AI portfolio with Bright Stock
The Net Income trend for Bright Minds Biosciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Bright Minds is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Bright Minds' Net Income Growth Pattern

Below is the plot of the Net Income of Bright Minds Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bright Minds Biosciences financial statement analysis. It represents the amount of money remaining after all of Bright Minds Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bright Minds' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bright Minds' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (12.23 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Bright Net Income Regression Statistics

Arithmetic Mean(4,115,153)
Coefficient Of Variation(129.09)
Mean Deviation4,688,639
Median(236,151)
Standard Deviation5,312,372
Sample Variance28.2T
Range14.7M
R-Value(0.77)
Mean Square Error12.1T
R-Squared0.60
Significance0.0003
Slope(812,447)
Total Sum of Squares451.5T

Bright Net Income History

2026-10.5 M
2025-11 M
2024-12.2 M
2023-2.8 M
2022-7.4 M
2021-15 M
2020-8.5 M

Other Fundumenentals of Bright Minds Biosciences

Bright Minds Net Income component correlations

Bright Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Bright Minds is extremely important. It helps to project a fair market value of Bright Stock properly, considering its historical fundamentals such as Net Income. Since Bright Minds' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bright Minds' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bright Minds' interrelated accounts and indicators.
Can Biotechnology industry sustain growth momentum? Does Bright have expansion opportunities? Factors like these will boost the valuation of Bright Minds. Projected growth potential of Bright fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Bright Minds demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(1.30)
Return On Assets
(0.19)
Return On Equity
(0.28)
Bright Minds Biosciences's market price often diverges from its book value, the accounting figure shown on Bright's balance sheet. Smart investors calculate Bright Minds' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Bright Minds' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bright Minds' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bright Minds should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bright Minds 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bright Minds' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bright Minds.
0.00
11/09/2025
No Change 0.00  0.0 
In 2 months and 31 days
02/07/2026
0.00
If you would invest  0.00  in Bright Minds on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Bright Minds Biosciences or generate 0.0% return on investment in Bright Minds over 90 days. Bright Minds is related to or competes with LB Pharmaceuticals, Design Therapeutics, Aura Biosciences, EnGene Holdings, DiaMedica Therapeutics, Altimmune, and Annexon. Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT medicines to improve the lives of patie... More

Bright Minds Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bright Minds' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bright Minds Biosciences upside and downside potential and time the market with a certain degree of confidence.

Bright Minds Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Bright Minds' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bright Minds' standard deviation. In reality, there are many statistical measures that can use Bright Minds historical prices to predict the future Bright Minds' volatility.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bright Minds' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
71.9576.7881.61
Details
Intrinsic
Valuation
LowRealHigh
68.4995.59100.42
Details
Naive
Forecast
LowNextHigh
60.3965.2270.04
Details
6 Analysts
Consensus
LowTargetHigh
139.88153.72170.63
Details

Bright Minds February 7, 2026 Technical Indicators

Bright Minds Biosciences Backtested Returns

Bright Minds appears to be very steady, given 3 months investment horizon. Bright Minds Biosciences secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had a 0.11 % return per unit of risk over the last 3 months. By analyzing Bright Minds' technical indicators, you can evaluate if the expected return of 0.52% is justified by implied risk. Please makes use of Bright Minds' Mean Deviation of 3.52, risk adjusted performance of 0.1275, and Downside Deviation of 4.09 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Bright Minds holds a performance score of 8. The firm shows a Beta (market volatility) of 2.21, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bright Minds will likely underperform. Please check Bright Minds' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether Bright Minds' price patterns will revert.

Auto-correlation

    
  -0.37  

Poor reverse predictability

Bright Minds Biosciences has poor reverse predictability. Overlapping area represents the amount of predictability between Bright Minds time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bright Minds Biosciences price movement. The serial correlation of -0.37 indicates that just about 37.0% of current Bright Minds price fluctuation can be explain by its past prices.
Correlation Coefficient-0.37
Spearman Rank Test-0.22
Residual Average0.0
Price Variance34.04
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Bright Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

2.42 Million

At this time, Bright Minds' Accumulated Other Comprehensive Income is most likely to increase significantly in the upcoming years.
Based on the recorded statements, Bright Minds Biosciences reported net income of (12.23 Million). This is 103.58% lower than that of the Biotechnology sector and 117.46% lower than that of the Health Care industry. The net income for all United States stocks is 102.14% higher than that of the company.

Bright Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bright Minds' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bright Minds could also be used in its relative valuation, which is a method of valuing Bright Minds by comparing valuation metrics of similar companies.
Bright Minds is currently under evaluation in net income category among its peers.

Bright Minds Current Valuation Drivers

We derive many important indicators used in calculating different scores of Bright Minds from analyzing Bright Minds' financial statements. These drivers represent accounts that assess Bright Minds' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bright Minds' important valuation drivers and their relationship over time.
202120222023202420252026 (projected)
Market Cap81.1M21.0M6.3M580.4M522.4M548.5M
Enterprise Value61.4M9.5M734.8K497.7M447.9M470.3M

Bright Minds ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bright Minds' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bright Minds' managers, analysts, and investors.
Environmental
Governance
Social

Bright Minds Institutional Holders

Institutional Holdings refers to the ownership stake in Bright Minds that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Bright Minds' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bright Minds' value.
Shares
Schonfeld Strategic Advisors Llc2025-06-30
69 K
Ikarian Capital, Llc2025-06-30
65.4 K
Geode Capital Management, Llc2025-06-30
57.5 K
Walleye Trading Advisors, Llc2025-06-30
53.4 K
Longwood Capital Partners Llc2025-06-30
48.5 K
Vanguard Group Inc2025-06-30
32 K
Junked Platinum Investment Management Ltd2025-06-30
28.3 K
Northern Trust Corp2025-06-30
25.6 K
State Street Corp2025-06-30
24.7 K
Hhg Plc2025-06-30
1.1 M
Cormorant Asset Management, Llc2025-06-30
1.1 M

Bright Fundamentals

About Bright Minds Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bright Minds Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bright Minds using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bright Minds Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:
Check out
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Can Biotechnology industry sustain growth momentum? Does Bright have expansion opportunities? Factors like these will boost the valuation of Bright Minds. Projected growth potential of Bright fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Bright Minds demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(1.30)
Return On Assets
(0.19)
Return On Equity
(0.28)
Bright Minds Biosciences's market price often diverges from its book value, the accounting figure shown on Bright's balance sheet. Smart investors calculate Bright Minds' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Bright Minds' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bright Minds' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bright Minds should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.